SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

BACKGROUND: Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkler, Claudia, Armenia, Joshua, Jones, Gemma N., Tobalina, Luis, Sale, Matthew J., Petreus, Tudor, Baird, Tarrion, Serra, Violeta, Wang, Anderson T., Lau, Alan, Garnett, Mathew J., Jaaks, Patricia, Coker, Elizabeth A., Pierce, Andrew J., O’Connor, Mark J., Leo, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921667/
https://www.ncbi.nlm.nih.gov/pubmed/33339894
http://dx.doi.org/10.1038/s41416-020-01199-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921667/
https://www.ncbi.nlm.nih.gov/pubmed/33339894
http://dx.doi.org/10.1038/s41416-020-01199-4

Ejemplares similares